Immunotherapy plus chemotherapy before surgery for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether combining immunotherapy with chemotherapy before surgery can help treat adenocarcinoma of the esophagus and stomach junction. It aims to improve outcomes for patients whose cancer can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of stomach cancer called adenocarcinoma of the esophagogastric junction.
- Your cancer must be able to be surgically removed (resectable) and not spread to other organs.
- You must be 18 years or older.
- You must be in good physical condition (ECOG score 0 or 1).
- You must not have had any previous cancer treatment like chemo, radiation, or surgery for this cancer.
- You must agree to use contraception if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether adding immunotherapy to chemotherapy before surgery works better than chemotherapy alone for resectable esophageal cancer. The goal is to improve outcomes after tumor shrinkage before the operation.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
This trial tests a drug called Adebrelimab combined with chemotherapy before surgery for esophageal cancer. It aims to shrink the tumor and make it easier to remove completely.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests combining immunotherapy (PD-1 blockers) with chemotherapy before surgery for advanced stomach cancer. The goal is to find the best number of treatment cycles to shrink the tumor and improve surgery results.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.